PURPOSE Lack of race- and age-diversity in clinical trials adversely affects generalizability of trial results and equity of trial access. Research on barriers to representative accrual has focused on patient-level factors. We aimed to define site-level factors affecting the diversity of accrual to a multicenter clinical trial. METHODS Alliance 191901 (GETSET) is a national randomized controlled trial testing interventions to promote breast cancer endocrine therapy adherence, which oversamples Black women and those under age 50 years at 30% thresholds. A secondary study objective is to examine site-level factors associated with accrual of Black and younger participants. At 50% accrual to the parent study, we performed prespecified analyses of association between site characteristics (region, neighborhood racial composition, Alliance membership type, number of recent accruals to cooperative research group trials) and the proportion of Black patients and younger patients accrued. We also examined trajectories of accrual over time for race- and age-specified subgroups. RESULTS The analysis included 124 sites. Among 590 participants, 9.7% were Black, and 22.4% were age <50 years. Neither site type nor historical accrual volume was associated with Black participant recruitment. Southern sites recruited higher proportions of Black participants (19.0% v 7.3% for West, P < .001). Neighborhood racial composition was positively associated with recruitment of Black participants (16.2% at sites from highest Black composition v 1.4% in lowest, P < .01). Recruitment trajectories of Black participants were slower than target rates, whereas those among non-Black participants were faster. CONCLUSION Neighborhood composition and geographic region were predictors of proportions of Black participants accrued to A191901 sites, but site type and historical accrual volume were not. When trials must limit site selection, identifying sites based on neighborhood composition and geography may be an appropriate tool for increasing trial diversity.
Voice and Choice: Voice Equivalence and Representational Choice in Virtual Health Assistants for Colorectal Cancer Screening Among Black American Adults
Proceedings of the 25th ACM International Conference on Intelligent Virtual Agents | October 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1-10
Abstract Introduction: The disproportionate prostate cancer (CaP) burden, which includes high mortality rates, is significantly attributed to the characteristics of the social determinants of the health status of the Black Male population. Designing targeted interventions to address poor health outcomes through a collaborative population-based approach could reduce CaP health disparities. The Community Living Lab (CoLLab) Learning Health System was developed to address ethnically sensitive, targeted approaches that will eliminate CaP health disparities among Black Men. This study assessed demographic factors and Knowledge on prostate cancer screening attitudes and research participation among black men. Method: The collab project employed a social ecological model to design intervention to address barriers to CaP screening and participation in clinical trials. A validated, pretested questionnaire was used to collect information on demographics, CaP knowledge, attitudes, testing, and a history of participation in research and clinical trials. Baseline data were collected from 3 American Legion posts (ALPs). The association between variables was evaluated using the Chi-square test. Results: Participants between 60-69 years were 28.38%, and those aged 40-49 were 12.16%. Most are US-born Black (89.8%), with others identifying as African-born Black (6.76%) and Caribbean-born Black (1.35%). Approximately 43.24% were retired, and 36.49% were working full-time. CaP knowledge was high in 43.9%, moderate in 46.6%, and low in 9.5%. Only 45% of the participants have undergone Prostate-Specific Antigen test, and 24.6% have had a Digital Rectal Examination. Reported past clinical trials and research participation were very low (9.38%). Participants with higher knowledge levels had higher information scores (p < .0001), favored various research settings (p = 0.0008), had favorable attitudes towards CaP testing (p < .0001), and were more likely to participate in research (p = 0.0117). Work status was found to impact CaP Knowledge (p = 0.0117). Participants with stronger beliefs about prostate cancer may have different attitudes toward testing (p = 0.0444). Age did not impact attitudes toward CaP testing (p = 0.4298). Conclusion: The knowledge of CaP was found to impact the attitudes, testing, and disposition of the participants towards research. The baseline data generated from the clinical study will curate insightful evidence that will create innovative approaches to prostate cancer education among males in Black communities. Citation Format: Opeyemi O. Bolajoko, Quincy A. Wimberly, Daniel W. Lee, Collisa Mahin, Michelle Fudge, Shaina E. Flynn, Arnold J. Merriweather, Trevanne R. Matthews Hew, Monica L. Albertie, Dery Greene, Wayne Ford, Toshiko Moultrie, Floyd B. Willis, Folakemi T. Odedina. Influence of demographic factors and knowledge on prostate cancer screening attitude and research participation among Black men [abstract]. In: Proceedings of the 18th AACR Conference on the Science of Cancer Health Disparities; 2025 Sep 18-21; Baltimore, MD. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2025;34(9 Suppl):Abstract nr C138.
Abstract C064: Feasibility of an interventional clinical trial addressing prostate cancer disparities in Black men by decentralization (DCT): A potential solution to disparities in clinical trial participation
Abstract Introduction: This ongoing study investigates the impact of vitamin D deficiency on the immune response to prostate cancer (CaP) in Black patients and its potential contribution to CaP disparities. The study also evaluates differences in immune function, including p53 and CaP associated antibody levels, in Black men with localized versus metastatic CaP. Methodology: Eligible patients with a history of localized or metastatic CaP are enrolled following informed consent (in person or remote). At baseline, blood is collected for calcium and vitamin D3 levels, and for immune testing. Patients who participate in the screening portion of the trial and are found to have vitamin D3 levels <30 ng/mL are prescribed oral vitamin D3 (2000 IU daily) and asked to record adherence in a medication diary. Follow-up includes a 4-week check-in and end-of-treatment labs at 8 weeks for calcium, vitamin D3 levels, and immune re-testing. Virtual consults occur after baseline and at 8 weeks. Quality of life is measured at baseline and EOT follow-up using the CDC HRQOL–4. The study began accruing patients in December 2021. In an attempt to accelerate patient accrual, the protocol was amended to become one of Mayo Clinic’s first fully decentralized clinical trials. Newly integrated components included at-home and community-based blood collection (outside of Mayo Clinic southern sites) and continued virtual engagement. These changes were designed to reduce barriers linked to social determinants of health (SDOH) and expand participation among medically underserved populations. This is a report on the impact of clinical trial DCT. Results: From December 2021 to September 2023 (pre-DCT), 24 patients were enrolled from 66 patients who participated in the screening portion for the trial (mean accrual: 1.09/month; SD: 1.15). Following the DCT amendment, enrollment rose to 102 patients from 213 screened (mean: 4.86/month; SD: 3.12) through June 2025. Of 126 enrolled patients, 119 (94.4%) returned medication diaries, with only 6 non-returns occurring post-DCT. QOL measures were completed by approximately 75% of participants. Importantly, 90 of 126 participants (71%) were enrolled from outside Jacksonville, FL or Scottsdale/Phoenix, AZ, indicating successful national expansion. A total of 111 patients failed the screening due to baseline vitamin D levels >30 ng/ml. The total number of protocol deviations increased post-DCT (60 from 10/23–6/25 vs. 14 from 12/21–9/23), there was no change in the number of protocol deviations per enrolled patients. Minor documentation and study timeline deviations were the most common in both periods. Conclusions: The successful implementation of a fully decentralized model was associated with a marked increase in the accrual of underserved patients and allows the completion of critical clinical trials that address important cancer care disparities without impacting protocol integrity. Clinical trial DCT can potentially reduce SDOH-related barriers and improve representation of underserved populations in research. Citation Format: Sandra Casanova Leyva, Kim M. Barbel Johnson, Tufia Haddad, Lydia Mercado, Trevanne Matthews Hew, Cassandra Moore, Gerardo Colon-Otero, Devina Joshi, Roselyn Heduvor. Feasibility of an interventional clinical trial addressing prostate cancer disparities in Black men by decentralization (DCT): A potential solution to disparities in clinical trial participation [abstract]. In: Proceedings of the 18th AACR Conference on the Science of Cancer Health Disparities; 2025 Sep 18-21; Baltimore, MD. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2025;34(9 Suppl):Abstract nr C064.
Abstract B048: A culturally tailored digital health platform to improve breast cancer survivorship for Black women: HERCaRE
Abstract Background: Black women continue to face disproportionate mortality and long-term challenges after breast cancer treatment, including gaps in follow-up care, culturally relevant support, and access to survivorship resources. Digital tools designed with Black survivors in mind remain limited, despite their potential to reduce disparities in post-treatment engagement. Objective: To address these gaps, we developed HERCaRE (Health Equity Resources for Breast Cancer Responsive Education), a progressive web application (PWA) designed to deliver culturally responsive survivorship education and engagement tools to Black breast cancer survivors. HERCaRE was designed to meet the need for a culturally responsive, easily accessible resource that empowers survivors to engage more confidently in their post-treatment care. Methods: The concept for HERCaRE was informed by a previous pilot study on virtual breast health education, in which participants expressed the need for more sustained and accessible support for survivors. Building on that insight, the platform was developed with advisory input from Black breast cancer survivors and community advocates through informal, discussion-based feedback. While not a formal co-design process, this input helped ensure cultural relevance in tone, structure, and visual language. HERCaRE includes three core features: educational modules on key survivorship topics, interactive behavior-prompting activities, and a notes section for self-reflection and goal tracking. The platform is grounded in the Health Promotion Model and RE-AIM framework, providing a foundation for future implementation and evaluation. The platform is currently being prepared for pilot testing, which will assess usability, perceived relevance, and engagement frequency among Black breast cancer survivors. Mixed-method surveys and platform analytics will guide refinement ahead of broader implementation. Preliminary Insights: Early input emphasized the importance of affirming, plain-language content and simple navigation. Activities were designed to promote exploration of the educational material and personal health behaviors through simple, self-guided prompts. Current efforts are focused on content finalization, participant recruitment, and platform readiness for testing. Conclusion: HERCaRE offers a responsive, theory-informed approach to digital survivorship support for Black women. While still in the pre-implementation phase, its development reflects a commitment to accessible design, cultural alignment, and future scalability. The platform lays important groundwork for reducing disparities in survivorship care and expanding digital health tools that center the needs of historically underserved populations. HERCaRE’s modular design and emphasis on user experience position it for adaptation across diverse clinical and community settings, including integration into survivorship programs serving other medically underserved populations. Citation Format: Manisha Salinas, Timethia Bonner, Laura Pacheco-Spann, Oluwadamilola Oladeru, Dianne Townsend, Che Ngufor. A culturally tailored digital health platform to improve breast cancer survivorship for Black women: HERCaRE [abstract]. In: Proceedings of the 18th AACR Conference on the Science of Cancer Health Disparities; 2025 Sep 18-21; Baltimore, MD. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2025;34(9 Suppl):Abstract nr B048.
Background Pseudohallucinations (PHs), defined as perceptual experiences recognized by the individual as unreal, have historically been distinguished from “true” hallucinations. However, their conceptual validity and clinical utility remain debated, with definitions and applications varying widely. Methods A narrative review of historical and contemporary literature on PHs was conducted. Articles were identified through PubMed using the terms “pseudohallucination,” “hallucination,” “dissociation,” and “trauma,” and through reviewing reference lists of key publications. Results Historical accounts emphasized features such as insight and localization, but empirical findings challenge these distinctions and demonstrate significant overlap with hallucinations and intrusive imagery across diagnoses. PHs are observed in psychotic, trauma-related, and personality disorders, suggesting they may reflect a spectrum of perceptual experiences rather than a discrete entity. Conclusions Moving beyond binary classifications and exploring the use of specifiers to describe hallucinations may offer a more nuanced framework for understanding these experiences across diagnostic categories. Rather than seeking rigid distinctions, this approach encourages descriptions that reflect individual phenomenology and context. Such a shift may help reduce stigma, foster more compassionate clinical engagement, and preserve the perceived relevance of the PH concept while aligning it with contemporary dimensional models of psychopathology.
Shaping Prostate Cancer Across the Care Continuum Among Black Men: The Role of Culture and Family Dynamics
Prostate cancer represents a significant health disparity among Black men, who experience higher rates of both incidence and mortality compared to other racial groups. Understanding the complex interplay of cultural, familial, and socioeconomic factors that shape health behaviors is essential for the development of effective interventions. This study sought to explore the lived experiences of ethnically diverse Black men with prostate cancer, focusing on how cultural context, family history, and spirituality influence health decisions and engagement with care. Through a secondary analysis of existing data, personal narratives from 32 Black prostate cancer survivors, primarily U.S.-born Black men, were examined to identify recurring themes that revealed the multifaceted challenges and motivations these men face. The analysis uncovered eight key themes that reflect a complex landscape, including medical distrust fueled by cultural perceptions and past negative experiences, the dual influence of family history on seeking early care versus hesitation, and the role of spirituality as a guiding force in health decisions. Additionally, financial constraints and limited access to comprehensive health information emerged as critical factors affecting engagement with preventive care. The findings underscore the need for culturally sensitive approaches that acknowledge the diverse experiences of Black men in their prostate cancer journey. By understanding the influence of family dynamics, spirituality, and socioeconomic challenges, future research can create targeted interventions that promote informed decision-making and help reduce disparities in prostate cancer outcomes.
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN‐TU‐001 trial
Abstract INTRODUCTION Monoclonal anti‐amyloid therapies are now accessible, but how these treatments influence changes within the brain is still not clear. We investigated overall and regional change in amyloid removal, glucose metabolism, and atrophy in trial participants with dominantly inherited Alzheimer's disease (DIAD). METHODS In the DIAN‐TU‐001 trial, 92 carriers received gantenerumab or placebo and underwent serial neuroimaging assessments including [ 11 C]‐Pittsburgh compound‐B (PiB) positron emission tomography (PET), [ 18 F]‐fluoro‐2‐deoxyglucose (FDG) PET, and magnetic resonance imaging (MRI). RESULTS Gantenerumab significantly reduced PiB‐PET uptake overall and in most regions and showed no changes in FDG‐PET or MRI measures. Drug effects were associated with baseline PiB‐PET uptake, and the largest effects occurred in medial regions. DISCUSSION Treated DIAD participants, and especially those with higher amyloid burden, showed a decrease in PiB‐PET uptake, which was more pronounced in the basal ganglia and medial frontal structures. These results may inform patient response and future drug trial design. Highlights Gantenerumab unevenly decreased Aβ burden as measured by PiB‐PET across brain regions. The strongest decrease in PiB‐PET uptake was in basal ganglia and medial frontal structures. Variable drug effect on Aβ was partly due to the amount of burden present before treatment. There was no regional effect on FDG‐PET metabolism or MRI volumetrics after 4 years.
CORR Insights®: Is There Any Association Between Orientation of the Lumbar Facet Joints and Increasing Age in White and Black Patients?
Plasma Metabolomics, Lipidomics, and Acylcarnitines Are Associated With Vision and Genotype but Not With Dietary Intake in Long‐Chain 3‐Hydroxyacyl‐
CoA
Dehydrogenase Deficiency (
ABSTRACT 3‐hydroxy acylcarnitines (3‐OH‐ACs) are key biomarkers for screening of long‐chain 3‐hydroxyacyl‐CoA dehydrogenase and trifunctional protein deficiencies (LCHADD/TFPD). The utility of this biomarker for disease monitoring in identified patients remains debated, and recent suggestions have highlighted the potential use of lipidomics for diagnosis, monitoring, prognosis, and/or identification of new biomarkers. We evaluated the use of omics in LCHADD/TFPD patients by analyzing plasma acylcarnitine profiles, metabolomics, and lipidomics, combined with genotype, visual assessments, and dietary records. Fasting plasma from 39 participants with LCHADD/TFPD and 32 control subjects were analyzed through untargeted metabolomic and lipidomic analyses. In LCHADD/TFPD participants, acylcarnitine profiling, visual and retinal function assessments were performed, and 3‐day diet records were collected. Relationships between acylcarnitines, metabolomics, lipidomics, along with visual outcomes and dietary intake were investigated. Plasma of LCHADD/TFPD participants exhibited elevated 3‐OH‐ACs, which correlated with genotype and visual outcomes. Metabolomics successfully distinguished LCHADD/TFPD from controls, and the biggest divergence was observed in lipid pathways. Metabolomic profiles tightly correlated with 3‐OH‐ACs, genotype, and visual outcomes. Lower concentrations of total lipids and some individual lipid species such as phosphoethanolamines (PE) were detected in LCHADD/TFPD, except for elevations in several certain triglycerides. LCHADD/TFPD participants followed a diet low in long‐chain fat (LCFA) as recommended. LCFA intake did not correlate with either plasma 3‐OH‐ACs or metabolomics. 3‐OH‐ACs are strong consistent biomarkers of LCHADD/TFPD that are associated with clinical parameters of vision and genotype. We did not observe a relationship between dietary LCFA intake and 3‐OH‐ACs.